Each year the American Society for Clinical Oncology (ASCO) publishes a report highlighting the steady progress that is being made in understanding and treating cancer. In this year’s report “Clinical Cancer Advances 2012: ASCO’s Annual Report on Progress Against Cancer”, four EORTC studies were among those selected as having the greatest potential impact on patients’ lives.
A study by Prof Winette van der Graaf et al., showed that targeted therapy with pazopanib prolongs progression free survival in advanced soft-tissue sarcoma. This article appeared in The Lancet and was considered a practice changing “major advance”.
An analysis by Chantal Quinten et al. which appeared in the Journal of the National Cancer Institute was considered a “notable advance” that offered promising clinical research results. This analysis showed that patients provide information that complements that of their doctors in predicting overall survival.
An abstract presented by Martin J. van den Bent et al. at the 2012 ASCO Annual meeting was also considered a “notable advance”. This study showed that giving combination chemotherapy after standard radiation therapy delayed tumor growth and extended the lives of patients with anaplastic oligodendroglial tumors, a hard-to-treat form of brain cancer.
Another “notable advance” was a retrospective analysis of clinical data from 342 patients who participated in EORTC Trial 40983 by Sorbye et al. This analysis, which appeared in the Annals of Surgery, revealed that perioperative FOLFOX seems to benefit a particular subset of patients with liver metastases from colorectal cancer.
EORTC, Medical Science Writer